Floatz logo

IBUPROFEN

Refractory T Acute Lymphoblastic Leukemia

City of Hope Medical CenterSmall moleculePhase 1Dormant
CC
47/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
32/ 100
Competitive Position
95/ 100

Competitive context

27 Active assets in the Refractory T Acute Lymphoblastic Leukemia cohort.

Asset / SponsorPhaseRating
DEXAMETHASONE
Princess Maxima Center for Pediatric Oncology
Phase 1/2CCC
Nelarabine
M.D. Anderson Cancer Center
Phase 1/2CCC
IMMUNOGLOBULIN G 1 (HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .GAMMA.1-CHAIN ANTI-HUMAN ANTIGEN CD 20), DISULFIDE WITH HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .KAPPA.-CHAIN, DIMER
M.D. Anderson Cancer Center
Phase 1/2CCC
PEGASPARGASE
M.D. Anderson Cancer Center
Phase 1/2CCC
Cpx-351
Children's Oncology Group
Phase 1/2CCC

View all 34 →

Same molecule, other indications

IBUPROFEN is also rated in:

chronic pain syndromeDormant
BBB
Indicative ·
72 / 100
View asset →
migraine disorderDormant
BBB
Indicative ·
72 / 100
View asset →
relapsing-remitting multiple sclerosisDormant
BB
Indicative ·
68 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →